VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a
provider of best-in-class therapeutic antibody discovery
capabilities for the global industry, today announced that its
wholly owned subsidiary U-Protein Express BV signed a long-term
lease contract for the new multi-tenant building for life sciences
"Accelerator" at the Utrecht Science Park (Utrecht, The Netherlands). In addition to
accommodating large biotechnology companies, the new building will
offer space to companies that want to accelerate their development.
The design is based on the vision of listed biotechnology companies
Genmab (NASDAQ:GMAB) and Merus (NASDAQ:MRUS): Improving lives of
patients by developing innovative therapies for cancer treatment,
partly by entering into valuable collaborations. Accelerator
endorses this ambition by creating a unique hub within the
innovation ecosystem.
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1064149/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_Subsidiary_Joins_Gen.jpg)
Accelerator offers Utrecht Science Park a welcome addition to
accommodate more innovative companies in the Life Sciences sector.
The building will be developed aiming for high sustainability
requirements (BREEAM Excellent) and will have a prominent place at
the entrance of Utrecht Science Park.
"We are happy to welcome U-Protein Express to Accelerator.
Accelerator is designed to facilitate and connect Life Sciences
companies, creating a tight international community within Utrecht
Science Park. U-Protein Express is a great addition to the
ecosystem and Accelerator will stimulate their growth ambitions,"
said Chiel van Dijen, Commercial
Director of Kadans Science Partner.
Dr. Martin Hessing, General
Manager of U-Protein Express, stated: "We are delighted to move our
continuously expanding service activities towards the new building
alongside important stakeholders such as Genmab and Merus. This
will enable us to keep in pace with our growing contract research
business as Accelerator will give us over 3-4 times current
capacity".
"The investments we are making in our European operations are a
strong reflection of ImunoPrecise's position in the marketplace and
positive outlook for the future," said Dr. Jennifer Bath, President and CEO. "The
Accelerator provides state-of-the-art facilities that enable our
talented team to respond to the increasing demand for our services
and innovative technologies."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell Select™ progressive single-cell
interrogation technology and the DeepDisplay™ custom,
OmniAb®-based phage libraries, as well as the
Abthena™ bispecific program. IPA is focused on the next
generation of antibody discovery, to deliver the most
therapeutically relevant antibodies, in a shorter period of time,
with the highest probability of succeeding to clinical trials.
ImmunoPrecise discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30, 2019 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.